What is PyrAmes?
Founded in 2016, PyrAmes operates at the intersection of advanced sensor engineering and clinical diagnostics. The company has engineered a sophisticated, wireless, and non-invasive platform designed to provide continuous blood pressure monitoring. By eliminating the need for traditional, cumbersome cuff-based systems, PyrAmes addresses a critical gap in patient care, offering a seamless integration for both hospital-based and remote monitoring environments. This technological advancement represents a paradigm shift in how clinicians track hemodynamic stability, moving toward a more proactive and data-centric model of patient management.
How much funding has PyrAmes raised?
PyrAmes has raised a total of $6M across 1 funding round:
Series A
$6M
Series A (2021): $6M with participation from Keystone Ventures, XTX Ventures, and GSR Ventures
Key Investors in PyrAmes
Keystone Ventures
A venture capital firm focused on identifying and scaling high-potential technology companies within the healthcare and life sciences sectors.
XTX Ventures
A strategic investment arm that supports innovative startups through capital and operational expertise, often focusing on data-driven technological advancements.
GSR Ventures
A prominent venture capital firm specializing in early-to-growth stage investments in the healthcare, AI, and enterprise software industries.
What's next for PyrAmes?
Following this major strategic investment, PyrAmes is poised to transition from its development-stage roots into a broader commercialization phase. The capital will likely be deployed to scale manufacturing capabilities, finalize regulatory milestones, and expand clinical validation studies. As the digital health landscape continues to prioritize remote patient monitoring and real-time diagnostics, PyrAmes is strategically aligned to capture significant market share. Future growth will depend on the successful integration of its sensor technology into existing healthcare ecosystems and the continued refinement of its proprietary algorithms to ensure clinical-grade accuracy across diverse patient populations.
See full PyrAmes company page
